Education
About Us
Working with TipRanks
Follow Us
Urogen Pharma (URGN)
NASDAQ:URGN
URGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.03 - $20.70
Previous CloseN/A
Volume157.75K
Average Volume (3M)416.32K
Market Cap
$509.80M
Enterprise Value$419.47M
Total Cash (Recent Filing)-$3.87M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.42
Next Earnings
May 08, 2025EPS Estimate
-0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.22
Shares Outstanding46,094,353
10 Day Avg. Volume443,176
30 Day Avg. Volume416,320
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.19
Price to Cash Flow (P/CF)-10.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.15
Enterprise Value/Ebitda-4.36
Forecast
1Y Price Target
$39.40Price Target Upside251.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Urogen Pharma News
PremiumCompany Announcements
UroGen Pharma’s Earnings Call Highlights Progress and Challenges
PremiumCompany Announcements
UroGen Pharma Reports Strong Pipeline Progress and Revenue Growth
---
Bulls Say, Bears Say
Bulls Say
Drug ApprovalThe FDA's acceptance of the NDA for UGN-102 with a set PDUFA date indicates a strong likelihood of approval.
Market OpportunityUGN-102 could become the first FDA-approved medicine for the treatment of low-grade, intermediate-risk, non-invasive bladder cancer, with a target market that may be larger than $5 billion annually.
Pipeline ExpansionThe recent in-licensing transaction broadens UroGen Pharma's early-stage pipeline and creates a constellation of candidates for bladder cancer.
Bears Say
Clinical Data UncertaintyProof-of-concept clinical data with ICVB-1042 in bladder cancer is awaited before attributing value to this program.
Financial PerformanceA modest revenue miss has been reported, affecting the financial outlook.
---
Ownership Overview
2.22% Insiders
2.41% Mutual Funds
47.24% Other Institutional Investors
42.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
URGN FAQ
What was Urogen Pharma’s price range in the past 12 months?
Urogen Pharma lowest stock price was $9.03 and its highest was $20.70 in the past 12 months.
What is Urogen Pharma’s market cap?
Urogen Pharma’s market cap is $509.80M.
When is Urogen Pharma’s upcoming earnings report date?
Urogen Pharma’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were Urogen Pharma’s earnings last quarter?
Urogen Pharma released its earnings results on Mar 10, 2025. The company reported -$0.8 earnings per share for the quarter, missing the consensus estimate of -$0.72 by -$0.08.
Is Urogen Pharma overvalued?
According to Wall Street analysts Urogen Pharma’s price is currently Undervalued.
Does Urogen Pharma pay dividends?
Urogen Pharma does not currently pay dividends.
What is Urogen Pharma’s EPS estimate?
Urogen Pharma’s EPS estimate is -0.8.
How many shares outstanding does Urogen Pharma have?
Urogen Pharma has 46,094,353 shares outstanding.
What happened to Urogen Pharma’s price movement after its last earnings report?
Urogen Pharma reported an EPS of -$0.8 in its last earnings report, missing expectations of -$0.72. Following the earnings report the stock price went up 1.018%.
Which hedge fund is a major shareholder of Urogen Pharma?
Currently, no hedge funds are holding shares in URGN
---
Urogen Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.40 (251.79% Upside)
$39.40 (251.79% Upside)
Blogger Sentiment
Bullish
URGN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 53.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.14%
12-Months-Change
Fundamentals
Return on Equity
-452.20%
Trailing 12-Months
Asset Growth
60.23%
Trailing 12-Months
Company Description
Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
---
URGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was generally positive, highlighting significant progress with the UGN-102 NDA submission, strong clinical trial results, and JELMYTO revenue growth. However, challenges include increased net loss and anticipated limitations in UGN-102's initial approval setting.Read More>---
URGN Stock 12 Month Forecast
Average Price Target
$39.40
▲(251.79% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Curis
―
Akebia Therapeutics
―
FibroGen
―
Blueprint Medicines
―
Best Analysts Covering URGN
1 Year
1 Year Success Rate
5/23 ratings generated profit
1 Year Average Return
-15.81%
reiterated a buy rating 6 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 21.74% of your transactions generating a profit, with an average return of -15.81% per trade.
---